Home›Stock Screener›Concord Biotech›Financial Statements

Concord Biotech Complete Financial Statements

7 Years of Data
2026 - 2020

In FY2026, Concord Biotech (CONCORDBIO) reported revenue ₹341 Cr, net profit ₹89 Cr and EPS ₹8.46, with a net profit margin of 26.1% and ROE of 4.4%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review Concord Biotech P/E valuation to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 26.10% 2026 data
EBITDA Margin 39.30% 2026 data
Operating Margin 36.00% 2026 data
Return on Assets 3.98% 2026 data
Return on Equity 4.41% 2026 data

Balance Sheet Ratios

Current Ratio 24.51 2026 data
Equity Ratio 90.25% 2026 data
Asset Turnover 0.15 2026 data

CONCORDBIO Revenue, Net Profit & EBITDA — Year-on-Year Growth

CONCORDBIO YoY (Mar 2025 vs Mar 2026) — revenue -22.3%, net profit -36.4%, EBITDA -32.3%, expenses -13.7%. Explore CONCORDBIO value investing to estimate fundamental worth using multiple valuation models.

Revenue Growth
-22.3%
Year-over-Year
Net Profit Growth
-36.4%
Year-over-Year
EBITDA Growth
-32.3%
Year-over-Year
Expense Growth
-13.7%
Year-over-Year
Assets Growth
+9.9%
Year-over-Year
Equity Growth
+11.3%
Year-over-Year
Operating Cash Flow Growth
-7.9%
Year-over-Year
Investing Cash Flow Growth
-3.2%
Year-over-Year

CONCORDBIO Income Statement — Revenue, EBITDA & Net Profit

Concord Biotech revenue ₹341 Cr, EBITDA ₹134 Cr, net profit ₹89 Cr, EPS ₹8.46 (2026) — net profit margin 26.1%. For live price, earnings ratios and company overview, see CONCORDBIO share price.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 Mar 2023 Jun 2023 Dec 2023 Sept 2022 Jun 2022 Dec 2022
Revenue 341 263 439 219 288 320 330 228 261 271 285 208 252 165 195 250
Expenses 208 159 241 143 183 177 187 135 146 147 146 123 135 122 116 131
EBITDA 134 104 198 77 105 144 143 93 115 124 139 85 117 44 79 119
Operating Profit Margin % 36.00% 36.00% 44.00% 30.00% 34.00% 43.00% 41.00% 38.00% 40.00% 44.00% 47.00% 37.00% 44.00% 24.00% 36.00% 46.00%
Depreciation 20 18 15 18 19 13 14 13 13 13 14 13 14 13 14 14
Interest 0 0 0 0 0 0 1 0 0 1 2 1 1 1 1 1
Profit Before Tax 114 86 184 59 86 130 129 80 101 110 124 71 103 30 64 105
Tax 26 23 43 15 23 35 34 20 25 29 32 17 26 8 15 27
Net Profit 89 63 140 44 64 96 95 60 76 81 92 55 78 22 49 77
Earnings Per Share (₹) 8.46 6.03 13.42 4.21 6.08 9.15 9.08 5.70 7.26 7.74 8.75 5.21 7.41 2.10 4.71 7.40

CONCORDBIO Balance Sheet — Assets, Liabilities & Shareholders' Equity

CONCORDBIO total assets ₹2,235 Cr, total equity ₹2,017 Cr, total liabilities ₹ Cr (2026) — ROE 4.4%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 2,235 2,034 1,701 1,514 1,313 1,183 941
Current Assets 1,250 1,135 896 728 633 607 539
Fixed Assets 871 795 575 593 573 546 240
Capital Work in Progress 78 51 212 173 74 18 141
Investments 326 335 246 137 74 141 199
Other Assets 0 854 668 611 592 477 361
LIABILITIES
Total Liabilities
Current Liabilities 51 38 32 32 54 77 55
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 2,017 1,813 1,527 1,290 1,103 999 770
Share Capital 11 11 11 11 10 10 10
Reserves & Surplus 2,007 1,802 1,516 1,280 1,094 990 761

CONCORDBIO Cash Flow Statement — Operating, Investing & Financing

Concord Biotech operating cash flow ₹245 Cr, investing ₹-160 Cr, financing ₹-99 Cr, net cash flow ₹-14 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities 245 266 246 208 167 155
Investing Activities -160 -155 -158 -112 -195 -114
Financing Activities -99 -99 -85 -100 31 -43
Net Cash Flow -14 12 3 -5 3 -1